RANSLOCATIONS involving chromosome region 1 lq23 occur in about 7% of acute lymphoblastic leukemia (ALL) with an exceptionally high incidence (70%) in infants.'" The spectrum of recombination partners comprise more than 20 different loci, with a predominance of t(4; 11) and t( 11 ; 19). fants and 34 adults) diagnosed between April 1989 and July 1993, of whom adequate cryopreserved cell material had been stored at the central immunologic laboratory of the trials and compared the incidence of ALLI-AF4-positive cases between this group of patients and 59 common ALLs (38 children, including one infant and 21 adults) as well as eight pre-B ALL (one child, seven adults) diagnosed over the same period.
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Immunophenotyping. Fresh bone marrow or peripheral blood samples were isolated by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation, and cell-surface antigens were detected by a standard indirect immunofluorescence (IF) assay, as previously described. 22 Nonspecific binding was avoided by adding heat-inactivated 10% rabbit serum in both the first and second incubations. Leukemic Leu-9, CD19/HD37, CD20/B1, CD24/OKB2), antimyeloid (CD13/ My7, CD33My9, CDw65NI"2), and nonlineage-specific reagents (CDIO/J5, CD34/My10, HLA-DWOKIal), all available from commercial sources. For cytoplasmic (cy) and nuclear straining, cytospin preparations of leukemic blasts were fixed in acetone (cyCD3, cyIgM) or methanol (terminal deoxynucleotidyl transferase, TdT), subsequently assayed by direct (cyIgM) or indirect IF using Leu-4 MoAb (cyCD3) or heterologous antisera (goat antimouse IgM, rabbit anti-TdT antiserum), and evaluated for IF by epifluorescence microscopy.
The results were considered positive if 220% (surface antigens) or 2 10% (intracytoplasmic/intranuclear antigens) of blasts reacted with the respective antibody.
For two-color IF measurements the directldirect method was applied by using VIM-2 (CDw65) and HD37 (CD19) MoAbs conjugated with fluorescein isothiocyanate and phycoerythrin, as described el~ewhere.2~
All cases were B-lineage in origin. On the basis of their pattern of reactivity, leukemic blasts were classified as pre-pre-B (CD19+, CD24', CDlO-, CD20-, cyIgM-), common (CD19+, CDlO+, cyIgM-) or pre-B ALL (CD19+, CDlO', cyIgM+, surface IgM-)."
Southern blot analysis. High molecular weight DNA was isolated from cryopreserved leukemia cells by standard techniques. Ten micrograms of genomic DNA was digested with BamHI or HindIII, separated in a 0.6% agarose gel, denatured, and blotted onto nylon filters (Nytran, Schleicher and Schuell, Dassel, Germany). Filters were hybridized to the 5' and 3' ALLl probes pEX5/GEB13 and pVAR8F/EX11B,8 respectively (kindly provided by Dr T.H. Rabbitts, Cambridge, UK).
PCR amplification and sequencing. RNA was isolated" from cryopreserved leukemia cells obtained at initial diagnosis or from bone marrow (BM) and peripheral blood (PB) cell samples of patients in complete remission. We also used the human leukemic cell lines RS4;l lZ6 and MV4;1Iz7 as positive, and CTV-lZ8 as negative controls for ALLl-AF4 fusion transcripts, respectively. cDNA was prepared from 10 pg of total RNA with random hexamer primers (Pharmacia) using a cDNA synthesis kit (Superscript, GIBCO-BRL, Gaithersburg, MD). The PCR amplification reactions contained 2 pL from a total of 20 pL cDNA, 30 pmol of each 5' and 3' oligonucleotide primer, 0.2 mmoVL of each deoxynucleotide triphosphate, 10 mmom TRIS-HCl pH 8.3, 50 mmoVL KC1,2.5 mmol/L MgCl', 0.001% gelatin (wtlvol), and 1 unit Taq polymerase (Amplitaq, Perkin Elmer, Nonvalk, CT). Denaturing, annealing, and extension steps were performed at 93°C for 60 seconds, 60°C for 90 seconds, and 72°C for 90 seconds, respectively, in an automatic PCR processor (BioMed, Theres, Germany) including an initial 3-mintue denaturation step at 93°C and a final extension step at 72°C for 10 minutes. Two microliters of the first round were used in a second round. For the analysis of ALLI-AF4 products in leukemia cell samples, both der (11) der (4) to we applied 35 and 30 cycles, respectively. The quality of RNA was controlled by amplification of AF4 sequences in a single round of PCR with 35 cycles. For the analysis of ALLI-ENL fusion transcripts, we used 35 cycles (first round) and 25 cycles (second round), respectively. PCR products (30 pL) were visualized by electrophoresis in 2.5% agarose gels stained with ethidium bromide. Scrupulous precautions were taken to avoid contaminati0n.2~
Oligomers were prepared using the solid-phase phosphate triester method according to ALL1," AF4,"." and ENL8 sequences. One ALLl primer was biotinylated at the 5' end to allow single strand isolation. Primer positions are indicated in Fig 1. We used the follow- For sequence analysis major PCR fragments were cut out from the gel and purified with Qiaex gel extraction kit (Qiagen Inc, Chatsworth, CA). A portion of the purified product was incubated for 45 minutes at room temperature in 30 pL STE (100 mmol/L NaCl, Dynabeads M280 streptavidin (Dynal, Hamburg, Germany). Dynabeads were collected via a Dynal MPC concentrator, washed in 200 pL 1 X STE, incubated with 100 pL 0.15 N NaOH for 15 minutes at m m temperature, and washed in 100 pL 0.15 N NaOH. Finally, single-stranded templates bound to the beads were washed twice in 200 pL H20 and resuspended in 10 pL H20. The supernatant of the denaturation step was directly precipitated with 0.2 mom Na-acetate pH 4.8, glycogen and 2.5 volume of ethanol, washed in 70% ethanol, and finally resuspended in 10 pL HzO. Minor amplification products were cloned into the PMOS blue T-vector according to methods described by the manufacturers (Amersham, Buckinghamshire, UK). We used the sequencing kit (Phannacia, Freiburg, Germany) following the instructions of the manufacturers together with the AF40 and ALL116 sequencing primers for analysis of the beads fraction Statistical analysis. Significance of the differences in leukocyte count and coexpression of myeloid antigens at the time of diagnosis between patients with and without ALLl-AF4 recombination was examined by the Wilcoxon-Mm-Whitney test and chi-square tests, respectively.M
RESULTS
Frequency of ALLl-AF4 recombinations. To estimate the frequency of ALLl-AF4 rearrangements in pre-preB ALL, we performed RT-PCR analysis in a relatively large series of 46 cases comprising 34 adults and 12 children (including four infants). Four children (33%) and 14 adults (41%) exhibited ALLl-AF4 transcripts. Clinical and immunophenotypic features of these patients (cases 1 through 18) are shown in Tables 1 and 2. Our data document a significant association of the ALL1-M4 recombination with coexpression of myeloid associated antigens, in particular CDw65 (P < .001), as compared with pre-pre-B ALL patients without this genetic anomaly (Table 3) . Moreover, a highly signifi- For to 24,500). To compare the incidence of ALL1-AF4 rearrangements with pre-pre-B ALL and other B-cell precursor subtypes, we also analyzed 59 common ALL and eight pre-B ALL patients. Only one ALL patient of each group, however, showed this genetic anomaly (cases 19 and 20, Tables 1 and  2 ). Karyotypic data were available from eight of the 20 ALL1-AF4-positive cases through the central cytogenetic laboratories of the multicenter ALL trials and showed a t(4;ll) in each patient (Table 4) . Moreover, all 48 ALL1-AF4-negative leukemias, of whom cytogenetic results were known, lacked this chromosomal defect. We were also able to study 10 of the ALL1-AF4-positive patients by Southern blot analysis and identified an ALLl recombination in all of them (Table 4) . Other than 4q21, over 20 different chromosomal regions have been identified, which may recombine with the ALLl locus on 1 lq23, and we reanalyzed by Southern blotting 15 of the ALL1-AF4-negative pre-pre-B ALL, of whom adequate cell material had been cryopreserved. In fact, three cases (two children, one adult) exhibited an ALLl rearrangement (Fig 2) . Unfortunately, karyotypic data were not available from these leukemias, but PCR analysis (not shown) disclosed in one patient an ALL1-ENL rearrangement corresponding to a t( 1 1 ; 19). Alternatively splicedfision transcripts. We next characterized the PCR fragments of the 20 ALL1-AF4-positive cases by sequence analysis. In virtually all patients, we observed one major amplification product together with one, two, or occasionally three additional fragments (Table 4 , Fig  3) . Overall, eight ALL1-AF4 versions were detectable. This large number of differently sized fusion transcripts results from alternative splicing events, Thus, case 1 (Fig 3) exhibits 669-bp, 555-bp, and 423-bp fragments representing ALL1-AF4 exons 8-b, 7-b, and 6-b junctions, respectively. A similarly heterogeneous pattern is observed in the other patients (Fig 3) , eg, case 13 (423-bp and 349-bp fragments corresponding to 6-b and 5-b junctions), case 8 (513-bp, 423-bp, and 381-bp fragments representing 7-c, 6-b, and 6-c junctions), case 15 (555-bp, 513-bp, and 423-bp fragments corresponding to 7-b, 7-c, and 6-b junctions), and case 16 (381-bp and 307-bp fragments representing 6-c and 5-c junctions). Moreover, ALL1-AF4 junctions containing AF4 exon b exist in two versions because of the alternate usage of two adjacent CAG trinucleotides at the splice acceptor site of this exon (not ~hown)!**~.~~~~ ' We also investigated the expression of reciprocal recombination products from the der (4) chromosome. Sufficient RNA was available from 17 of the 20 ALL1-AF4-positive patients and showed AF4-ALL1 transcripts in 11 cases (65%). Similar to the situation on the der (1 1) chromosome, multiple amplification products emerged per patient from the der (4) fusion because of alternative splicing. Sequence analysis of the major products showed AF4-ALL1 RNA species, which generally correspond precisely to the reciprocal transcripts from the der (1 1) chromosome, although skipping of one or two ALLl exons was observed in patients No. 4 through 6 and 19 (Table 4) .
Detection of minimal residual disease. Nine of the 20 ALL1-AF4-positive leukemia patients are presently in con- Table l) . Four of them received an autologous or allogeneic bone marrow transplant (BMT) in the course of treatment. We were able to obtain 12 BM and PB samples of seven pre-pre-B ALL patients for the analysis of residual leukemia (Table 5) . A series of dilution experiments using cell lines RS 4;11 and MV 4;ll established that our PCR conditions reliably allow the detection of one ALLI-AF4-positive cell among IO5 to 10' cells (Fig  4) . Interestingly, all 12 remission samples lacked evidence of ALLl-AF4 fusion transcripts in repeated experiments including Southern transfer from respective gels and consecutive hybridization with ALL1 probes.
Control analyses of the same samples readily detected AF4 amplification products even under standard PCR conditions (Fig 4) .
DISCUSSION
In this study, we show a significantly higher frequency of ALLI-AF4 recombinations in ALL patients with a pre-pre-B phenotype as compared with other B-cell precursor leukemias. Taking into account overall incidences of 5% and 1 1% of the pre-pre-B subtype in the ongoing German multicenter trials for children and adults, respectively, our results match well with cytogenetic analyses that have identified a t(4;ll) in 2% to 4% of ALL patients.'.2 ALL1 at 1 lq23 is notorious for its promiscuous involvement in more than 20 different chromosomal abnormalities.3 Along this line 10.6% (3 of 28) of the ALLl-AF4-negative pre-pre-B leukemias in the present study showed an ALL1 recombination. In one patient, the fusion partner could be identified as the ENL gene on 19~13. Thus, it is possible that about 45% of pre-pre-B ALL may exhibit ALLI-recombinations. Our data also show a significant association of ALLI-AF4-positive ALL with distinct clinical and phenotypic characteristics, namely hyperleukocytosis and coexpression of myeloid markers, thereby confirming previous reports based on cytogenetic4.' or moIecuIar' investigations. The ALLl-AF4 fusion generates a large set of alternatively spliced transcripts.'.''.'" In our series, sequence analysis identified eight different versions representing combinations of ALL1 exons 5, 6, 7, or 8 with AF4 exons b or c. Additional heterogeneity stems from two adjacent CAG trinucleotides at the intron-exon-boundary of AF4 exon b resulting in minor codon variation in respective splice juncspecies with predominant expression of one transcript. The biologic significance, if any, of this heterogeneity among ALLl-AF4 RNA species remains enigmatic. Moreover, the leukemogenic potential of ALL1-AF4 products still awaits formal proof by in vitro or in vivo studies. Transcription from the reciprocal der (4) chromosome represents a less consistent event and has been found in 11 of 17 cases (65%) in our study and in 16 of 19 patients (84%) in a recent report,16 respectively. A similar situation is observed in acute promyelocytic leukemia characterized by t(l5; 17). Here, PML-RARa transcripts are found in all patients, but the corresponding RARu-PML transcripts and proteins in only two thirds of cases.32 At the present time, the oncogenic potential of reciprocal AF4-ALL1 or RARa-PML products has not been defined by in vitro or in vivo assays. Therefore, their role in leukemogenesis is far from being clear.
The t(4;ll) in ALL has been associated with a very poor tionS~'.'J.l".."
In every patient, we identified two or three RNA prognosis. However, recently various high-risk leukemia subgroups have improved substantially following the introduction of intensified treatment strategie~.'~ This issue cannot sufficiently be addressed in the present study and awaits prospective evaluation in the ongoing multicenter trials. Yet, it appears noteworthy that nine of the 19 ALLl-AF4-positive leukemias with adequate follow-up remain in complete remission for up to 54 months (median, 26 months). This outcome may be partly attributed to the fact that four patients received marrow transplants.
The most interesting result of this report emerges from PCR analysis of BM and PB samples obtained from seven patients in complete remission. In fact, none of the 12 samples showed evidence for minimal residual disease. This observation in conjunction with a recent report on serial PCR analysis in two ALLI-AF4-positive ALL patientsIs demonstrates the possibility to reduce the leukemia clone below the detection level of PCR. These data may encourage current efforts to induce and maintain remissions in respective patients by intense protocols. Along the same line PCRnegativity has recently been established as a therapeutic goal in acute promyelocytic leukemia. 
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to evaluate the significance of minimal residual disease independently for each hematopoietic neoplasia, taking into account biologic and genetic discrepancies, as well as different treatment modalities.
